🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tübingen
Clinical trial register · Germany

Clinical Trials in Tübingen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 40 Munich 26 Dresden 22 Essen 21 Tübingen 20
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin40 Munich26 Dresden22 Essen21 Tübingen20
All 98 locations
Target enrolment
to

Trials with a site in Tübingen

20 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
NCT07286149Lung Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 1/2
140
Tübingen
2026-04-30
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC
Phase 1/2
170
Tübingen, Jena
2026-01-29
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 3
904
Stuttgart, Tübingen, Göttingen, Schwerin, Herne, Münster, Dresden, Erfurt
2025-11-26
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
50
Tübingen, Münster
2025-05-26
Recruiting
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06780085Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
Phase 2
96
Tübingen, Berlin
2025-05-13
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Freiburg im Breisgau, Ludwigsburg, Tübingen, Erlangen, Munich, Potsdam, Georgsmarienhütte, Hanover
2024-06-24
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC
Phase 1/2
220
Heidelberg, Tübingen, Munich, Berlin, Hamburg
2024-05-20
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Heilbronn, Mannheim, Ravensburg, Tübingen, Munich, Essen, Dresden, Berlin
2023-12-06
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
Singen, Tübingen, Munich, Aachen, Bonn, Düsseldorf, Essen, Münster
2022-03-15
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle
2021-04-21
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Tübingen, Düsseldorf, Essen, Dresden, Magdeburg, Jena, Berlin, Hamburg
2020-02-27
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
Merck Sharp & Dohme LLC
Phase 3
714
Tübingen, Ulm, Erlangen, Munich, München, Frankfurt am Main, Kassel, Cologne
2018-12-17
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
Merck Sharp & Dohme LLC
Phase 3
976
Mannheim, Tübingen, Munich, Nuremberg, Würzburg, Buxtehude, Hanover, Essen
2018-09-12
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Tübingen, Erlangen, Munich, Frankfurt am Main, Buxtehude, Hanover, Essen, Homburg
2018-08-21
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/t-bingen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Tübingen that also match the filters currently applied.

How many clinical trials are recruiting in Tübingen?

11 of the 20 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tübingen), 20 studies
PhaseStudiesRecruitingShare
Phase 312360%
Phase 1/25525%
Phase 23315%

Most active sponsors

Lead sponsors with the most studies (Tübingen)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2011
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.